长春新碱对口腔鳞癌中Stathmin调控作用的实验研究

doi:10.19439/j.sjos.2022.01.001

上海口腔医学 ›› 2022, Vol. 31 ›› Issue (1): 1-5.doi: 10.19439/j.sjos.2022.01.001

长春新碱对口腔鳞癌中Stathmin调控作用的实验研究

谈亦然, 赵铜超, 琚梧桐^*, 钟来平^*

上海交通大学医学院附属第九人民医院口腔颌面-头颈肿瘤科,上海交通大学口腔医学院,国家口腔医学中心,国家口腔疾病临床医学研究中心,上海市口腔医学重点实验室,上海 200011

收稿日期:2020-11-02 修回日期:2021-03-16 出版日期:2022-02-25 发布日期:2022-03-10
通讯作者: 琚梧桐,E-mail：juwutong@163.com;钟来平,E-mail：zhonglaiping@163.com。^*共同通信作者
作者简介:谈亦然（1988-）,男,医师,硕士,E-mail：gordon-tan@foxmail.com
基金资助:
国家自然科学基金（81972525,81672660）; 上海市卫生健康委员会学科带头人计划（2018BR41）; 上海交通大学医学院附属第九人民医院临床研究型MDT项目（201916）

Experimental investigation of vincristine on chemosensitivity through Stathmin regulation in oral squamous cell carcinoma

TAN Yi-ran, ZHAO Tong-chao, JU Wu-tong, ZHONG Lai-ping

Department of Oromaxillofacial Head and Neck Oncology, Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School of Medicine; College of Stomatology, Shanghai Jiao Tong University; National Center for Stomatology; National Clinical Research Center for Oral Diseases; Shanghai Key Laboratory of Stomatology. Shanghai 200011, China

Received:2020-11-02 Revised:2021-03-16 Online:2022-02-25 Published:2022-03-10

摘要/Abstract

摘要： 目的: 先前的研究发现,微管解聚蛋白（Stathmin）是潜在的指导局部晚期口腔鳞癌诱导化疗的生物标志物,本研究旨在进一步探索长春新碱对Stathmin的调控作用以及其作为TPF化疗替代药物的潜能。方法: 构建Stathmin过表达及敲减稳转细胞系,通过细胞增殖试验、q-PCR、Western免疫印迹、皮下移植瘤等实验方法,采用SPSS 23.0软件包进行统计学差异分析。结果: 长春新碱可抑制口腔鳞癌细胞系Stathmin的表达。高表达Stathmin后,口腔鳞癌细胞系对长春新碱的敏感性提高。针对高表达Stathmin的口腔鳞癌细胞系移植瘤,长春新碱具有良好的抑瘤效果。结论: 对于高表达Stathmin的口腔鳞癌,长春新碱是潜在的替代化疗药物。

关键词: 口腔鳞癌, 微管解聚蛋白, 长春新碱, 个体化治疗

Abstract: PURPOSE: Our previous studies have found that Stathmin, a microtubule depolymerizing protein, is a potential biomarker to guide locally advanced oral squamous cell carcinoma (OSCC) induction chemotherapy. This study further explored the regulatory effect of vincristine on Stathmin and its potention as an alternative chemotherapy drug. METHODS: Stathmin overexpressed and knockdown stable cell lines were constructed. Cell proliferation, q-PCR, Western blot, subcutaneous xenograft and other experimental methods were used to value the regulatory effect of vincristine on Stathmin. The differences were statistically analyzed with SPSS 23.0 software package. RESULTS: Vincristine inhibited the expression of Stathmin in OSCC cell lines. The sensitivity to vincristine was increased in Stathmin overexpressed OSCC cell lines. Vincristine had potent anti-tumor effect for OSCC cell line xenografts with higher Stathmin expression. CONCLUSIONS: Vincristine is a potential alternative chemotherapeutic agent for OSCC with higher Stathmin expression.

Key words: Oral squamous cell carcinoma, Microtubule depolymerizing protein, Vincristine, Individualized treatment

中图分类号:

R739.8

谈亦然, 赵铜超, 琚梧桐, 钟来平. 长春新碱对口腔鳞癌中Stathmin调控作用的实验研究[J]. 上海口腔医学, 2022, 31(1): 1-5.

TAN Yi-ran, ZHAO Tong-chao, JU Wu-tong, ZHONG Lai-ping. Experimental investigation of vincristine on chemosensitivity through Stathmin regulation in oral squamous cell carcinoma[J]. Shanghai Journal of Stomatology, 2022, 31(1): 1-5.

参考文献

[1] Zhong LP, Zhang ZY.Reply to K. Devisetty et al[J]. J Clin Oncol, 2013, 31(23): 2972-2973.
[2] Zhong LP, Zhang CP, Ren GX, et al.Randomized phase Ⅲ trial of induction chemotherapy with docetaxel, cisplatin, and fluorouracil followed by surgery versus up-front surgery in locally advanced resectable oral squamous cell carcinoma[J]. J Clin Oncol, 2013, 31(6): 744-751.
[3] Niethammer P, Bastiaens P, Karsenti E.Stathmin-tubulin interaction gradients in motile and mitotic cells[J]. Science, 2004, 303(5665): 1862-1866.
[4] Baquero MT, Hanna JA, Neumeister V, et al.Stathmin expression and its relationship to microtubule-associated protein tau and outcome in breast cancer[J]. Cancer, 2012, 118(19): 4660-4669.
[5] Nie W, Xu MD, Gan L, et al.Overexpression of stathmin 1 is a poor prognostic biomarker in non-small cell lung cancer[J]. Lab Invest, 2015, 95(1): 56-64.
[6] Biaoxue R, Xiguang C, Hua L, et al.Stathmin-dependent molecular targeting therapy for malignant tumor: the latest 5 years' discoveries and developments[J]. J Transl Med, 2016, 14(1): 279-297.
[7] Johnsson A, Zeelenberg I, Min Y, et al.Identification of genes differentially expressed in association with acquired cisplatin resistance[J]. Br J Cancer, 2000, 83(8): 1047-1054.
[8] Lin X, Liao Y, Xie J, et al.Op18/stathmin is involved in the resistance of taxol among different epithelial carcinoma cell lines[J]. Cancer Biother Radiopharm, 2014, 29(9): 376-386.
[9] Ju WT, Ma HL, Zhao TC, et al.Stathmin guides personalized therapy in oral squamous cell carcinoma[J]. Cancer Sci, 2020, 111(4): 1303-1313.
[10] Bai S, Zhang BY, Dong Y.Impact of taxanes on androgen receptor signaling[J]. Asian J Androl, 2019, 21(3): 249-252.
[11] Florian S, Mitchison TJ.Anti-microtubule drugs[J]. Methods Mol Biol, 2016,1413: 403-421.
[12] Nishio K, Nakamura T, Koh Y, et al.Oncoprotein 18 overexpression increases the sensitivity to vindesine in the human lung carcinoma cells[J]. Cancer, 2001, 91(8): 1494-1499.
[13] Takahashi M, Yang XJ, Lavery TT, et al.Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features[J]. Cancer Res, 2002, 62(22): 6598-6605.
[14] Gleeson M, Peckitt C, To YM, et al.CHOP versus GEM-P in previously untreated patients with peripheral T-cell lymp-homa(CHEMO-T): a phase 2, multicentre, randomised, open-label trial[J]. Lancet Haematol, 2018, 5(5): e190-e200.
[15] Watanabe T, Tobinai K, Wakabayashi M, et al.Outcomes after R-CHOP in patients with newly diagnosed advanced follicular lymphoma: a 10-year follow-up analysis of the JCOG0203 trial[J]. Lancet Haematol, 2018, 5(11): e520-e531.
[16] Luo Z, Zhang X, Peng W, et al.A phase Ⅱ study of gemcitabine, vincristine, and cisplatin as second-line treatment for patients with advanced soft tissue sarcoma[J]. Medicine (Baltimore), 2015, 94(43): e1777-e1782.
[17] Li WP, Liu H, Chen L, et al.A clinical comparison of lobaplatin or cisplatin with mitomycine and vincristine in treating patients with cervical squamous carcinoma[J]. Asian Pac J Cancer Prev, 2015, 16(11): 4629-4631.
[18] Tokunaga H, Nagase S, Yoshinaga K, et al.Small cell carcinoma of the uterine cervix: clinical outcome of concurrent chemoradiotherapy with a multidrug regimen[J]. Tohoku J Exp Med, 2013, 229(1): 75-81.
[19] Verrills NM, Liem NL, Liaw TY, et al.Proteomic analysis reveals a novel role for the actin cytoskeleton in vincristine resistant childhood leukemia-an in vivo study[J]. Proteomics, 2006, 6(5): 1681-1694.

长春新碱对口腔鳞癌中Stathmin调控作用的实验研究

Experimental investigation of vincristine on chemosensitivity through Stathmin regulation in oral squamous cell carcinoma

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	谢玉婷, 熊屏. 基于单原子铁纳米催化剂的纳米催化疗法对口腔鳞癌细胞Cal27的作用[J]. 上海口腔医学, 2024, 33(2): 117-122.
[2]	段咏华, 吴开柳, 梅健, 周谊渊, 刘梦石. 口腔鳞癌组织中RACK1与EGP40的表达及其与临床病理特征及预后的相关性[J]. 上海口腔医学, 2023, 32(4): 385-390.
[3]	董淋升, 唐进, 程维, 冉婧璇, 刘兆博, 李雅冬. IL-6和β-catenin在口腔鳞癌中的表达及预后价值[J]. 上海口腔医学, 2023, 32(3): 280-286.
[4]	胡小媛, 王宁, 张晓野, 杨茜, 高菲, 王成勤, 尚伟, 项锋钢, 冯元勇. Chemerin对口腔鳞癌中性粒细胞浸润的影响及机制探讨[J]. 上海口腔医学, 2023, 32(2): 158-165.
[5]	郭梦瑶, 李凯玉, 聂敏海, 刘旭倩. 上调Decorin对口腔鳞癌荷瘤裸鼠EGFR、C-Myc、p21表达的影响[J]. 上海口腔医学, 2023, 32(1): 40-46.
[6]	文旭涛, 马振, 张翀, 陶识丞, 陈兴金, 麦华明. 不同培养条件对CD133⁺原代口腔鳞癌细胞干性维持的影响[J]. 上海口腔医学, 2022, 31(4): 343-348.
[7]	秦志明, 揭伟萍, 池彦廷, 李宏锋, 李斌斌. 基于局部可变阈值的无监督定量Ki-67细胞增殖指数模型的初步建立[J]. 上海口腔医学, 2022, 31(3): 248-254.
[8]	买尔哈巴·买合木提, 拜婕, 如斯坦木·依米提, 姚志涛. 50例口腔鳞癌患者治疗过程中营养状况改变及影响因素分析[J]. 上海口腔医学, 2022, 31(2): 205-210.
[9]	谢非, 秦星, 童桐, 蒋英英, 张建军. IGF2BP1在口腔鳞癌细胞耐药中的作用及机制探讨[J]. 上海口腔医学, 2021, 30(5): 456-461.
[10]	李蕾, 李晓东, 庄乾伟, 葛良玉, 李志萍, 顾倩平, 白玉婷, 孟箭. 超声热疗联合TPF化疗治疗19例老年晚期口腔鳞癌的疗效分析[J]. 上海口腔医学, 2021, 30(5): 543-547.
[11]	邵小钧, 朱乔, 刘有, 韩小东, 林小臻, 席庆. 咀嚼槟榔与口腔鳞癌的相关临床病理学因素分析[J]. 上海口腔医学, 2021, 30(3): 268-272.
[12]	薛佳艺, 朱晓燕, 危常磊, 孙培, 张慧, 邓婧. 25例口腔鳞癌患者唾液代谢组学分析[J]. 上海口腔医学, 2021, 30(2): 201-205.
[13]	王树斌, 秦帅华, 易雅群, 李新明. 216例口腔鳞癌患者术后心理困扰影响因素及放疗前、后生存质量评价[J]. 上海口腔医学, 2021, 30(1): 71-76.
[14]	傅宗云, 陶峰. MMP-14、ING4和HIF-1α在60例口腔鳞癌中的表达及临床意义[J]. 上海口腔医学, 2020, 29(6): 642-646.
[15]	王学梅, 蒋勇. 双硫仑对口腔鳞癌细胞上皮-间充质转化的影响及机制探讨[J]. 上海口腔医学, 2020, 29(2): 138-145.